BioCardia's Cash Boosted by Offerings Amidst Mounting Losses

TL;DR

**BCDA is burning cash and diluting shareholders to stay afloat, with a going concern warning that screams 'high risk' for any new money.**

AI Summary

BioCardia, Inc. (BCDA) reported a net loss of $1.48 million for the three months ended September 30, 2025, an improvement from a net loss of $1.74 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $6.24 million, compared to $5.65 million in 2024. The company generated no collaboration agreement revenue in the three and nine months ended September 30, 2025, a decrease from $58,000 in revenue for the nine months ended September 30, 2024. Research and development expenses increased to $3.83 million for the nine months ended September 30, 2025, up from $2.97 million in the prior year, while selling, general and administrative expenses decreased to $2.43 million from $2.77 million. Cash and cash equivalents significantly increased to $5.29 million as of September 30, 2025, from $2.37 million at December 31, 2024, primarily due to $7.86 million in net cash provided by financing activities. The company's accumulated deficit reached $166.37 million, and management believes current cash is insufficient to fund operations beyond the second quarter of 2026, raising substantial doubt about its ability to continue as a going concern.

Why It Matters

BioCardia's continued reliance on equity financing to sustain operations, evidenced by $7.86 million in net cash from financing activities, signals a high-risk profile for investors. While the increased cash balance to $5.29 million provides a temporary reprieve, the substantial accumulated deficit of $166.37 million and projected funding shortfall by Q2 2026 highlight the precarious financial position. This ongoing need for capital could lead to further dilution for existing shareholders, impacting stock value. For employees, the going concern warning creates job uncertainty, and for customers and the broader market, the viability of BioCardia's promising cardiovascular and pulmonary disease therapies, such as CardiAMP, remains contingent on successful future funding rounds and clinical trial outcomes, placing it in a challenging competitive landscape against better-capitalized biotechs.

Risk Assessment

Risk Level: high — BioCardia has an accumulated deficit of approximately $166.4 million as of September 30, 2025, and management explicitly states that current cash and cash equivalents of $5.3 million are not sufficient to fund planned expenditures beyond the second quarter of 2026. These factors raise substantial doubt about the company's ability to continue as a going concern, indicating a significant financial risk.

Analyst Insight

Investors should exercise extreme caution and consider avoiding BCDA given the explicit going concern warning and continuous dilution. Those holding shares should evaluate their risk tolerance and potential for further capital raises that could dilute their stake.

Financial Highlights

debt To Equity

1.34

revenue

$0

operating Margin

N/A

total Assets

$6.15M

total Debt

$3.52M

net Income

-$1.48M

eps

-$0.24

gross Margin

N/A

cash Position

$5.29M

revenue Growth

-100.0%

Revenue Breakdown

Key Numbers

• $1.48M — Net Loss (Q3 2025) (Improved from $1.74M in Q3 2024)
• $6.24M — Net Loss (9M 2025) (Increased from $5.65M in 9M 2024)
• $5.29M — Cash & Cash Equivalents (As of September 30, 2025, up from $2.37M at Dec 31, 2024)
• $166.37M — Accumulated Deficit (As of September 30, 2025, indicating significant historical losses)
• $7.86M — Net Cash from Financing (For the nine months ended September 30, 2025, crucial for liquidity)
• 10,612,734 — Shares Outstanding (As of November 11, 2025, reflecting significant dilution from 4,600,910 shares at Dec 31, 2024)
• $3.83M — R&D Expenses (9M 2025) (Increased from $2.97M in 9M 2024, indicating ongoing trial costs)
• $2.43M — SG&A Expenses (9M 2025) (Decreased from $2.77M in 9M 2024)

Key Players & Entities

• BioCardia, Inc. (company) — clinical-stage company focused on developing cellular and cell-derived therapeutics
• SEC (regulator) — Securities and Exchange Commission
• Nasdaq Capital Market (market) — exchange where BCDA Common Stock is registered
• $1.48 million (dollar_amount) — net loss for the three months ended September 30, 2025
• $1.74 million (dollar_amount) — net loss for the three months ended September 30, 2024
• $6.24 million (dollar_amount) — net loss for the nine months ended September 30, 2025
• $5.65 million (dollar_amount) — net loss for the nine months ended September 30, 2024
• $5.29 million (dollar_amount) — cash and cash equivalents as of September 30, 2025
• $166.4 million (dollar_amount) — accumulated deficit as of September 30, 2025
• second quarter of 2026 (date) — period beyond which current cash is not sufficient to fund operations

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: Management believes current cash is insufficient to fund operations beyond the second quarter of 2026. This raises substantial doubt about BioCardia's ability to continue as a going concern.
• Significant Accumulated Deficit [high — financial]: The company has an accumulated deficit of $166.37 million as of September 30, 2025, indicating a history of net losses and a substantial need for future funding.
• Increased R&D Expenses [medium — financial]: Research and development expenses increased to $3.83 million for the nine months ended September 30, 2025, up from $2.97 million in the prior year, likely reflecting ongoing clinical trial costs.
• Dependence on Financing [high — financial]: The significant increase in cash to $5.29 million as of September 30, 2025, was primarily driven by $7.86 million in net cash provided by financing activities, highlighting reliance on external funding.
• Share Dilution [medium — financial]: Shares outstanding increased substantially to 10,612,734 as of November 11, 2025, from 4,600,910 at December 31, 2024, indicating significant dilution for existing shareholders.
• Lack of Revenue Generation [medium — operational]: The company generated no collaboration agreement revenue in the first nine months of 2025, a decrease from $58,000 in the same period of 2024, indicating challenges in commercializing its technology or securing partnerships.

Industry Context

BioCardia operates in the highly competitive and capital-intensive biotechnology sector, focusing on cell and gene therapies for cardiovascular diseases. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success often depends on securing substantial funding for clinical trials and navigating complex approval processes.

Regulatory Implications

As a biotechnology company developing novel therapies, BioCardia is subject to stringent regulatory oversight from bodies like the FDA. Delays in clinical trials, adverse safety findings, or failure to meet efficacy endpoints can lead to significant setbacks and increased costs, impacting the company's ability to achieve regulatory approval.

What Investors Should Do

1. Monitor cash burn and future financing activities closely.
2. Evaluate the progress and cost-effectiveness of R&D efforts.
3. Assess the impact of share dilution on existing holdings.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported net loss of $1.48 million and cash of $5.29 million. Accumulated deficit reached $166.37 million.
• 2024-09-30: End of Q3 2024 — Reported net loss of $1.74 million. Collaboration revenue was $0 for the quarter.
• 2026-06-30: Projected cash runway end — Management estimates current cash will not be sufficient to fund operations beyond this date, indicating an urgent need for capital.
• 2025-11-11: Shares Outstanding Date — 10,612,734 shares outstanding, a significant increase from December 31, 2024, indicating substantial dilution.

Glossary

Accumulated deficit

The total net losses of a company since its inception that have not been offset by net income. (Indicates BioCardia's historical unprofitability, reaching $166.37 million as of September 30, 2025.)

Going concern

A business's ability to continue operating for the foreseeable future without the threat of liquidation. (Management's doubt about BioCardia's ability to continue as a going concern beyond Q2 2026 is a critical risk factor.)

Collaboration agreement revenue

Revenue generated from partnerships or agreements with other companies for joint development or commercialization efforts. (The absence of this revenue ($0 for 9M 2025) highlights a lack of current income from strategic partnerships.)

Net cash provided by financing activities

The net amount of cash generated or used in activities related to debt, equity, and dividends. (This was the primary driver of BioCardia's increased cash balance, with $7.86 million for the nine months ended September 30, 2025.)

Dilution

The reduction in the value of existing shareholders' equity resulting from the issuance of new shares. (The significant increase in shares outstanding points to substantial dilution for current investors.)

Year-Over-Year Comparison

BioCardia reported a narrower net loss of $1.48 million for Q3 2025 compared to $1.74 million in Q3 2024, though the nine-month net loss widened to $6.24 million from $5.65 million. Revenue from collaboration agreements has ceased entirely. While R&D expenses increased, SG&A expenses decreased. The company significantly bolstered its cash position to $5.29 million, primarily through financing, but faces substantial doubt about its going concern status due to an insufficient cash runway beyond Q2 2026. Shareholder equity has improved, but the accumulated deficit remains substantial at $166.37 million.

Key Financial Figures

• $0.001 B — ch registered Common Stock, par value $0.001 BCDA The Nasdaq Capital Market Indicat
• $250,000 — mes exceeds federally insured limits of $250,000 per customer. On September 30, 2025, ap

Filing Documents

• bcda20250930_10q.htm (10-Q) — 838KB
• ex_880983.htm (EX-31.1) — 10KB
• ex_880982.htm (EX-31.2) — 10KB
• ex_880981.htm (EX-32.1) — 4KB
• ex_880980.htm (EX-32.2) — 4KB
• 0001437749-25-034437.txt ( ) — 4179KB
• bcda-20250930.xsd (EX-101.SCH) — 42KB
• bcda-20250930_def.xml (EX-101.DEF) — 263KB
• bcda-20250930_lab.xml (EX-101.LAB) — 230KB
• bcda-20250930_pre.xml (EX-101.PRE) — 292KB
• bcda-20250930_cal.xml (EX-101.CAL) — 26KB
• bcda20250930_10q_htm.xml (XML) — 596KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 12 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 20 Item 4.

Controls and Procedures

Controls and Procedures 20 Part II. OTHER INFORMATION 21 Item 1.

Legal Proceedings

Legal Proceedings 21 Item 1A.

Risk Factors

Risk Factors 21 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 21 Item 3. Defaults Upon Senior Securities 21 Item 4. Mine Safety Disclosures 21 Item 5. Other Information 21 Item 6. Exhibits 22 EXHIBIT INDEX 22

SIGNATURES

SIGNATURES 23 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or report, contains forward-looking statements within the meaning of the U.S. federal securities laws that involve risks and uncertainties. Certain statements contained in this report are not purely historical including, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the development of our cell therapy systems, our clinical trials, and our business development initiatives, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or resources or other financial items, (iii) our need and ability to raise additional capital, (iv) our future financial performance, including any such statement contained in a discussion and analysis of financial condition by management or in the results of operations included pursuant to the rules and regulations of the SEC, (v) our ability to develop and advance current product candidates and programs and execute on our corporate strategy and (vi) the assumptions underlying or relating to any statement described in points (i) – (v) above. These statements include those discussed in Item 2, Management ' s Discussion and Analysis of Financial Condition and Results of Operations, including " Critical Accounting Policies and Estimates, " " Results of Operations, " " Liquidity and Capital Resources, " and " Future Funding Requirements, " and elsewhere in this report. In this report, the words " may, " " could, " " would, " " might, " " will, " " should, " " plan, " " forecast, " " anticipate, " " believe, " " expect, " " intend, " " estimate, " " predict, " " potential, " " continue, " " future, " " moving toward " or the negative of these terms or other similar expressions also identify forward-looking statements. Our actual results could dif

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS BIOCARDIA, INC. Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts) September 30, December 31, 2025 2024 (unaudited) Assets Current assets: Cash and cash equivalents $ 5,287 $ 2,371 Prepaid expenses and other current assets 78 251 Total current assets 5,365 2,622 Property and equipment, net 13 33 Operating lease right-of-use asset, net 599 898 Other assets 171 171 Total assets $ 6,148 $ 3,724 Liabilities and Stockholders ' Equity Current liabilities: Accounts payable $ 1,080 $ 385 Accrued expenses and other current liabilities 1,803 1,551 Operating lease liability - current 427 385 Total current liabilities 3,310 2,321 Operating lease liability - noncurrent 211 566 Total liabilities 3,521 2,887 Commitments and contingencies (Notes 2, 5 and 11) Stockholders' equity: Preferred stock, $ 0.001 par value, 25,000,000 shares authorized and no shares issued and outstanding as of September 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value, 50,000,000 shares authorized, 10,608,734 and 4,600,910 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 11 5 Additional paid-in capital 168,981 160,953 Accumulated deficit ( 166,365 ) ( 160,121 ) Total stockholders' equity 2,627 837 Total liabilities and stockholders' equity $ 6,148 $ 3,724 See accompanying notes to the unaudited condensed consolidated financial statements. 1 BIOCARDIA, INC. Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts) (unaudited) Three months ended Nine months ended September 30, September 30, 2025 2024 2025 2024 Revenue: Collaboration agreement revenue $ — $ — $ — $ 58 Costs and expenses: Research and development 936 931 3,834 2,972 Selling,

View Full Filing

View this 10-Q filing on SEC EDGAR